Phase 2 study of induction immunotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for locally advanced esophageal squamous cell carcinoma

Long-term survival after definitive concurrent chemoradiotherapy (dCCRT) remains limited in locally advanced esophageal squamous cell carcinoma (LA ESCC). A phase 2 study at Shanghai Jiao Tong University School of Medicine (China) evaluated induction immunochemotherapy followed by dCCRT and consolidation immunotherapy in this setting. The study enrolled 54 adults selected for definitive nonsurgical treatment. The planned regimen comprised two cycles of induction immunochemotherapy with nab-paclitaxel, carboplatin, and a PD-1 inhibitor, followed by dCCRT with 50.4 Gy in 28 fractions and concurrent weekly chemotherapy. The same PD-1 inhibitor was planned as consolidation therapy for up to 1 year. The primary endpoint was 2-year overall survival (OS) rate. Fifty-three patients (98.1%) completed two induction cycles, all 54 proceeded to dCCRT, and 31 (57.4%) received consolidation immunotherapy. Among all 54 patients, the median follow-up was 28.1 months. The 2-year OS rate was 84.6% (95% CI 75.2-95.0) and the 2-year progression-free survival (PFS) rate was 61.5% (49.5-76.4). Adverse events occurred predominantly during dCCRT and were mainly hematologic. Exploratory analyses suggested that suboptimal response after induction immunochemotherapy was associated with shorter PFS. The authors conclude that the survival outcomes observed with this sequential approach support further evaluation in randomized studies (graphical abstract).